You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

CLINICAL TRIALS PROFILE FOR VENLAFAXINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for VENLAFAXINE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT05875610 ↗ Preventive Approach Using Venlafaxine Recruiting Mit Ghamr Oncology Center Phase 4 2023-05-01 Peripheral and Motor neuropathy represent a main obstacle for a better quality of life for cancer patients, Venlafaxine is introduced in a new dosing regimen for treating of oxaliplatin and taxanes induced peripheral neuropathy in cancer patients.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for VENLAFAXINE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001483 ↗ Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression Completed National Institute of Mental Health (NIMH) Phase 2 1995-06-01 This study will compare the effectiveness of relatively new antidepressants which have different mechanisms of action. Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway. Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI). Venlafaxine (Effexor) works as a mixed serotonin, norepinephrine, and dopamine reuptake inhibitor. Subjects enrolled in this study will be patients diagnosed with a bipolar disorder who are presently taking medication to prevent the symptoms of the disease (prophylactic treatment), but have had breakthrough episodes of depression despite taking their medication. Patients will receive any one of the three antidepressant medications as noted above plus a placebo inactive sugar pill, in order to mask which antidepressant is being prescribed) in addition to their regular medication for bipolar disorder. All of the doses will be calculated as effective for the treatment of a unipolar major depressive disorder. The patient will continue receiving the medication for ten weeks. The effectiveness of the drug treatment will be measured by using three different scales; 1. Inventory for Depressive Symptoms - Clinicians form (IDS-C) 2. Clinical Global Impression scale(CGI-BP) 3. Life Charting Methodology (LCM) Patients who do not respond to their medication within ten weeks from the beginning of the study will be considered as non-responders and be offered the opportunity to start the study again, taking one of the two remaining medications. For example, if a patient was assigned to take Wellbutrin but it was ineffective, he/she could re-enter the study and be given either Zoloft or Effexor. Patients that do respond in the first ten weeks of the study will be eligible to continue taking the medication for one year to assess the long term effectiveness of the drug on preventing episodes of depression and to assess for any possible differential induction of mania.
NCT00018902 ↗ Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) Completed National Institute of Mental Health (NIMH) Phase 2/Phase 3 2001-01-01 The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
NCT00018902 ↗ Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) Completed University of Pittsburgh Phase 2/Phase 3 2001-01-01 The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for VENLAFAXINE HYDROCHLORIDE

Condition Name

Condition Name for VENLAFAXINE HYDROCHLORIDE
Intervention Trials
Depression 41
Major Depressive Disorder 36
Healthy 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for VENLAFAXINE HYDROCHLORIDE
Intervention Trials
Depression 101
Depressive Disorder 89
Depressive Disorder, Major 61
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for VENLAFAXINE HYDROCHLORIDE

Trials by Country

Trials by Country for VENLAFAXINE HYDROCHLORIDE
Location Trials
United States 370
Canada 51
China 27
Japan 22
Australia 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for VENLAFAXINE HYDROCHLORIDE
Location Trials
Pennsylvania 26
California 24
New York 23
Massachusetts 17
Florida 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for VENLAFAXINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for VENLAFAXINE HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 71
Phase 3 40
Phase 2/Phase 3 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for VENLAFAXINE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 141
Unknown status 18
Not yet recruiting 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VENLAFAXINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for VENLAFAXINE HYDROCHLORIDE
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 19
National Institute of Mental Health (NIMH) 15
New York State Psychiatric Institute 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for VENLAFAXINE HYDROCHLORIDE
Sponsor Trials
Other 222
Industry 90
NIH 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.